ClinicalTrials.gg
CompletedNCT04747964Updated Sep 19, 2024

A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

A Phase 1 interventional study of STSP-0601 for Injection and STSP-0601 for Injection in Hemophilia, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2020, registered Feb 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Enrollment
64th of 80
16 · median 54
Started
2020
with 5 others
Phase 1
13 of 93
4 open now
Registered
41st of 93
by date
Lead sponsor
4 of 93
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Among the 93 studies in Hemophilia A with a site in China, this one is the 64th largest by enrollment of the 80 interventional ones that give a count, is one of 6 that started in 2020, is one of 13 in phase 1, and was the 41st registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

This study will assess the pharmacokinetics and pharmacodynamics of STSP-0601 at six dose levels. The results will help identify the most optimal doses to treat bleedings in hemophilia patients with inhibitors.

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old ≤age≤65 years of age,male.
  • Hemophilia A or B patients with inhibitors.
  • Peak historical inhibitor titer ≥ 5 BU and a positive inhibitor test when enrolled.
  • Establish proper venous access.
  • Provide signed .

Exclusion criteria

Exclusion Criteria:

  • Have any coagulation disorder other than hemophilia A or B.
  • Treat with prophylactic treatment of coagulation factor.
  • Treat with anticoagulant within 7d of the time of study drug administration.
  • Have an active, ongoing bleeding for which the patient is being treated, or treatment for a bleeding was stopped within 7d of the time of study drug administration.
  • Have a history of arterial and/or venous thromboembolic events.
  • Have count \<100,000/mL.
  • Severe liver or kidney disease.
  • Accept major operation or blood transfusion within 1 month of the time of screening.
  • antibody positive.
  • Have a known allergy to Blood product.
  • Participate in other clinical research within 1 month of the time of study drug administration.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    A single lowest dose of treatment group

    Drug: STSP-0601 for Injection

  • Experimental
    A single low dose of treatment group

    Drug: STSP-0601 for Injection

  • Experimental
    A single low-intermediate dose of treatment group

    Drug: STSP-0601 for Injection

  • Experimental
    A single intermediate dose of treatment group

    Drug: STSP-0601 for Injection

  • Experimental
    A single high dose of treatment group

    Drug: STSP-0601 for Injection

  • Experimental
    A single highest dose of treatment group

    Drug: STSP-0601 for Injection

Interventions

  • Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements

  • Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements

  • Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements

  • Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements

  • Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements

  • Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements

06

What researchers measure

Primary outcomes

  1. Number of subjects of adverse events

    Time frame: Baseline to Day 8

  2. Number of subjects With Significant Abnormal Physical Examination

    Time frame: Baseline to Day 8

  3. Number of subjects of Significant Abnormal Vital Signs Findings

    Time frame: Baseline to Day 8

  4. Number of Participants With Significant Abnormal Laboratory Values

    Time frame: Baseline to Day 8

  5. Number of subjects With Significant Abnormal Electrocardiography (ECG) Findings

    Time frame: Baseline,1 hour,4 hour,48 hour,Day 8

Secondary outcomes

  1. Activated partial thromboplastin time

    Time frame: Baseline to 24 hours

  2. Thrombin production (TG) peak

    Time frame: Baseline to 24 hours

07

Study locations

1 site
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
    Tianjin, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Apr 2021, 15 months.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 15 months is above that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2021
First posted
Feb 10, 2021
StartActual
Jan 15, 2020
Primary completionActual
Apr 19, 2021
CompletionActual
Apr 19, 2021
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04747964
Responsible party
Sponsor
First posted
Feb 10, 2021
Start date
Jan 15, 2020
Primary completion
Apr 19, 2021
Completion
Apr 19, 2021
Last update
Sep 19, 2024

Study contacts

Lei Zhang
principal investigator · Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STSP-0601

Start the discussion